Cellectar reports financial results for third quarter 2022 and provides a corporate update

Florham park, n.j., nov. 03, 2022 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the third quarter ended september 30, 2022 and provided a corporate update.
CLRB Ratings Summary
CLRB Quant Ranking